Article
Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2010
Camidge D Ross, Kono Scott A, Flacco Antonella, Tan Aik-Choon, Doebele Robert C, Zhou Qing, Crino Lucio, Franklin Wilbur A, Varella-Garcia Marileila
Abstract excerpt
PURPOSE: Anaplastic lymphoma kinase (ALK) rearrangements, associated with sensitivity to an experimental ALK/MET inhibitor, occur in 3% to 5% of non-small cell lung cancers. Intratumoral fluorescence in situ hybridization (FISH) heterogeneity has been reported. We explored the heterogeneity basis...
Topics
- Anaplastic Lymphoma Kinase
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Genetic Testing
- Humans
- In Situ Hybridization, Fluorescence
- Lung Neoplasms
- Mutation
- Pharmacogenetics
- Protein Kinase Inhibitors
- Receptor Protein-Tyrosine Kinases
- Structure-Activity Relationship